Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Please use this identifier to cite or link to this item: http://hdl.handle.net/11690/1780

Authors:	Veiga, Viviane C. Prats, João A. G. G. Farias, Danielle L. C. Rosa, Regis G. Dourado, Leticia K. Zampieri, Fernando G. Machado, Flávia R. Lopes, Renato D. Berwanger, Otavio Azevedo, Luciano C. P. Avezum, Álvaro Lisboa, Thiago Rojas, Salomón S. O. Coelho, Juliana C. Leite, Rodrigo T. Carvalho, Júlio C. Andrade, Luis E. C. Sandes, Alex F. Pintão, Maria C. T. Castro Junior, Claudio G. Santos, Sueli V. de Almeida, Thiago M. L. Costa, André N. Gebara, Otávio C. E. Freitas, Flávio G. Rezende de Pacheco, Eduardo S. Machado, David J. B. Martin, Josiane Conceição, Fábio G. Siqueira, Suellen R. R. Damiani, Lucas P. Ishihara, Luciana M. Schneider, Daniel Souza, Denise de Cavalcanti, Alexandre B. Scheinberg, Phillip
Title:	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
Keywords:	COVID-19
Issue Date:	2021
Publisher:	BMJ Publishing Group
Citation:	VEIGA, V. C. et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, v. 372, n. 84, jun. 2021. Disponível em: http://hdl.handle.net/11690/1780. Acesso em: 08 jul. 2021.
Appears in Collections:	Artigo de Periódico (PPGSDH)

Files in This Item:

File	Description	Size	Format
Effect Tocilizumab_BMJ.pdf	Open Access	421,25 kB	Adobe PDF	View/Open